Cash gives pharma an M&A edge
Despite the financial crisis and near-standstill in dealmaking, some cash-rich sectors such as pharmaceuticals have seen an uptick in M&A activity, according to a study by Ernst & Young LLP’s transaction advisory services.
“With more than three dozen drugs set to lose patent protection over the next several years, the need to reinvigorate pharmaceutical pipelines is [...]
http://feeds.reuters.com/~r/reuters/blogs/reuters-dealzone/~3/d2ZWOFX7nzo/